This assay is therefore highly sensitive to compounds that inhibit PA-CMG2 interactions and could be used to effectively generate lead compounds for cancer, other angiogenesis related diseases, and anthrax toxin therapies. The gene discussed is ANTXR2; the disease is cancer.